Literature DB >> 26188919

Paired measurement of serum amyloid A (SAA) and paraoxonase 1 (PON1) as useful markers in breast cancer recurrence.

Christine Bobin-Dubigeon1, Armelle Lefrançois2, Jean-Marc Classe3, Marie-Pierre Joalland2, Jean-Marie Bard4.   

Abstract

OBJECTIVES: Paraoxonase 1 (PON1) and serum amyloid A (SAA) are carried by HDL. In case of inflammation, SAA and PON1 tend to change in opposite direction. In this study we determined if inflammation leads to altered PON1 activity using three different substrate hydrolysis rates, paraoxonase (PON), arylesterase (ARE) and lactonase (LAC) in breast cancer recurrence. DESIGN AND METHODS: 49 patients with a recurrence of breast cancer were analyzed for SAA, CRP, lipids, oxidized LDL, PON, ARE and LAC. Distribution of PON1 activities across the quartiles of CRP and SAA were compared by the Kruskal Wallis test. Non-parametric estimates of the survivor function were computed with Kaplan-Meier method. The association of SAA and ARE with short term death was assessed by logistic regression models.
RESULTS: HDL and ARE decrease significantly across the quartiles of CRP. No significant differences were observed across SAA quartiles. The survival time was significantly related to the level of SAA (log rank: p<0.001) as well as the level of ARE (log rank: p=0.039). SAA and ARE were independently related to survival time below one year.
CONCLUSIONS: PON1 does not seem to be directly affected by SAA, for any of the tested substrates, PON, ARE and LAC. The combined measurement of SAA and ARE could be a useful tool in this clinical situation, since they are independently related to short term death.
Copyright © 2015 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Inflammation; Paraoxonase; SAA

Mesh:

Substances:

Year:  2015        PMID: 26188919     DOI: 10.1016/j.clinbiochem.2015.07.020

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  5 in total

1.  Effect of radiotherapy on activity and concentration of serum paraoxonase-1 in breast cancer patients.

Authors:  Meritxell Arenas; Anabel García-Heredia; Noemí Cabré; Fedra Luciano-Mateo; Anna Hernández-Aguilera; Sebastià Sabater; Marta Bonet; Marina Gascón; Salvador Fernández-Arroyo; Isabel Fort-Gallifa; Jordi Camps; Jorge Joven
Journal:  PLoS One       Date:  2017-11-27       Impact factor: 3.240

2.  Evaluation of the prognostic value of paraoxonase 1 in the recurrence and metastasis of hepatocellular carcinoma and establishment of a liver-specific predictive model of survival.

Authors:  Zheng Yu; Qifeng Ou; Fan Chen; Jiong Bi; Wen Li; Jieyi Ma; Rongchang Wang; Xiaohui Huang
Journal:  J Transl Med       Date:  2018-11-26       Impact factor: 5.531

3.  Serum amyloid A predisposes inflammatory tumor microenvironment in triple negative breast cancer.

Authors:  Rosa Mistica C Ignacio; Carla R Gibbs; Soohyun Kim; Eun-Sook Lee; Samuel E Adunyah; Deok-Soo Son
Journal:  Oncotarget       Date:  2019-01-11

4.  PON1 hypermethylation is associated with progression of renal cell carcinoma.

Authors:  Xin Li; Qian Yu
Journal:  J Cell Mol Med       Date:  2019-08-10       Impact factor: 5.310

5.  Acute-phase serum amyloid A for early detection of hepatocellular carcinoma in cirrhotic patients with low AFP level.

Authors:  Jin-Lin Wu; Tung-Hung Su; Pei-Jer Chen; Yun-Ru Chen
Journal:  Sci Rep       Date:  2022-04-06       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.